GCO Financials

Income Statement
MetricQ1 2027Q4 2026Q3 2026Q2 2026Q1 2026
Revenue
487.0M
-39.1%
799.9M
+29.8%
616.2M
+12.9%
546.0M
+15.2%
474.0M
Cost of Revenue
258.1M
-40.4%
432.8M
+32.1%
327.6M
+10.7%
296.0M
+17.1%
252.8M
Gross Profit
228.9M
-37.6%
367.1M
+27.2%
288.6M
+15.5%
249.9M
+13.0%
221.2M
Operating Expenses
244.3M
-22.6%
315.8M
+12.8%
280.1M
+5.9%
264.5M
+6.1%
249.3M
R&D
0
0
0
0
0
SG&A
254.4M
-18.6%
312.4M
+13.3%
275.7M
+4.3%
264.3M
+6.1%
249.0M
Operating Income
-15377000
-130.0%
51.3M
+498.4%
8.6M
+158.8%
-14588000
+48.2%
-28145000
EBITDA
-12237000
-118.1%
67.7M
+157.9%
26.3M
+2753.4%
-990000
+93.2%
-14461000
Net Income
-14814000
-131.1%
47.6M
+788.9%
5.4M
+129.0%
-18471000
+13.0%
-21227000
EPS (Basic)
$-1.42
-130.9%
$4.60
+784.6%
$0.52
+129.1%
$-1.79
+11.4%
$-2.02
EPS (Diluted)
$-1.42
-132.9%
$4.32
+764.0%
$0.50
+127.9%
$-1.79
+11.4%
$-2.02
Shares (Diluted)
10.4M
-5.5%
11.0M
+3.4%
10.7M
+3.7%
10.3M
-1.9%
10.5M
Genes (GCO) โ€” Financials